FluidForm Bio, Inc. — SEC Form D Filing
FluidForm Bio, Inc. filed an SEC Form D on August 27, 2026, reporting $1.70M raised in Biotechnology.
Form D filing details
- Filing
- SEC Form D
- Filing date
- August 27, 2026
- Amount reported
- $1.70M
- Round stage
- Seed, as the amount raised of $1,703,371 is typical for early-stage biotechnology companies developing foundational technology.
- Industry
- Biotechnology
- Website
- https://www.fluidformbio.com
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
The pharmaceutical, medical device, and regenerative medicine industries face challenges in developing and testing new treatments and products due to the limitations of traditional tissue models and animal testing.
Solution
FluidForm Bio builds living human tissue using its FRESH 3D bioprinting technology to provide advanced models for drug discovery, device testing, and regenerative medicine applications.
Why now
Advances in 3D bioprinting technology and increasing demand for more accurate and ethical human tissue models are enabling the development of complex living tissues.
Source: SEC EDGAR Form D filing